Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Amitriptyline

Related Products

Hot Products

Name

Amitriptyline

EINECS 200-041-6
CAS No. 50-48-6 Density 1.076 g/cm3
PSA 3.24000 LogP 4.97060
Solubility water: 9.7 mg/mL Melting Point 196-197 °C
Formula C20H23N Boiling Point 398.2 °C at 760 mmHg
Molecular Weight 277.409 Flash Point 174 °C
Transport Information N/A Appearance N/A
Safety Risk Codes R36/37/38
Molecular Structure Molecular Structure of 50-48-6 (Amitriptyline) Hazard Symbols Xi
Synonyms

5H-Dibenzo[a,d]cycloheptene-D5,g-propylamine, 10,11-dihydro-N,N-dimethyl- (6CI,8CI);5-(g-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene;Adepress;Amitriptylin;Damilen;MK 230;N 750;Proheptadiene;Seroten;Triptanol;Triptisol;

Article Data 40

Amitriptyline Synthetic route

4317-14-0

Amitriptyline N-oxide

50-48-6

Amitriptyline

Conditions
ConditionsYield
With sodium tetrahydroborate In water at 50 - 60℃; chemoselective reaction;98%
50-00-0

formaldehyd

4444-42-2

Desmethylnortriptyline

50-48-6

Amitriptyline

Conditions
ConditionsYield
With formic acid; triethylamine In water; tert-butyl alcohol at 100℃; for 14h;89%
1159-03-1

5-(3-dimethylaminopropyl)-10,11-dihydrodibenzo[a,d]cyclohepten-5-ol

50-48-6

Amitriptyline

Conditions
ConditionsYield
In ethanol at 200℃; under 82508.3 Torr; for 0.01h; Solvent; Temperature; Flow reactor;78%
124-38-9

carbon dioxide

72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

50-48-6

Amitriptyline

Conditions
ConditionsYield
With diphenylsilane; [1,3-bis(2,4,6-trimethylphenyl)imidazol]-2-ylidene In N,N-dimethyl-formamide at 50℃; under 760.051 Torr; chemoselective reaction;63%
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 24h; Autoclave; Inert atmosphere;81 %Chromat.

N,N-dimethyl-4-(2-phenethylphenyl)but-3-yn-1-amine

50-48-6

Amitriptyline

Conditions
ConditionsYield
With trifluorormethanesulfonic acid In dichloromethane at 0℃; for 0.166667h; Friedel-Crafts Alkylation; regioselective reaction;56%
3433-80-5

1-Bromo-2-bromomethyl-benzene

50-48-6

Amitriptyline

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: n-butyllithium; carbon dioxide / tetrahydrofuran; hexane / -50 - 20 °C / 3878.71 Torr / Flow reactor
2: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor
3: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor
View Scheme
Multi-step reaction with 3 steps
1: n-butyllithium; carbon dioxide / tetrahydrofuran; hexane / -50 - 20 °C / Flow reactor
2: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor
3: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor
View Scheme
1210-35-1

10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one

50-48-6

Amitriptyline

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor
2: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor
View Scheme
64-18-6

formic acid

72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

50-48-6

Amitriptyline

Conditions
ConditionsYield
With platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex; 1,3-bis-(diphenylphosphino)propane; phenylsilane In dibutyl ether at 60℃; for 18h; Schlenk technique; Inert atmosphere;94 %Chromat.

C19H20O3S

50-48-6

Amitriptyline

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ethanol; water / 2 h / 50 °C
2: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
583-55-1

1-Bromo-2-iodobenzene

50-48-6

Amitriptyline

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: bis-triphenylphosphine-palladium(II) chloride; triethylamine; copper(l) iodide / acetonitrile / 22 h / 0 - 20 °C
2: hydrogen; palladium 10% on activated carbon / ethyl acetate / 6 h / 20 °C
3: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C
4: triethylamine / dichloromethane / 2.5 h / 0 °C
5: ethanol; water / 2 h / 50 °C
6: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme

Amitriptyline Chemical Properties

Molecular Structure:

Molecular Formula: C20H23N
Molecular Weight: 277.4033
IUPAC Name: (3S,4R)-3-(1,3-Benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
Synonyms of Amitriptyline (CAS NO.50-48-6): 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene ; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine ; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin ; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine ; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene ; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene ; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene ; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene ; 5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl- ; Adepress ; Adepril ; Amitriptilina ; Amitriptilina [INN-Spanish] ; Amitriptilina [Italian] ; Amitriptylin ; Amitriptylin [German] ; Amitriptylinum ; Amitriptylinum [INN-Latin] ; Amytriptylin ; BRN 2217885 ; CCRIS 9174 ; Damilen ; Damitriptyline ; EINECS 200-041-6 ; Elavil ; Flavyl ; Lantron ; MK 230 ; N 750 ; Proheptadiene ; Redomex ; Ro 4-1575 ; Seroten ; Triptanol ; Triptilin ; Triptisol ; Tryptanol ; UNII-1806D8D52K ; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- ; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-
CAS NO: 50-48-6
Classification Code: Adrenergic Agents ; Adrenergic uptake inhibitors ; Analgesics ; Analgesics, Non-Narcotic ; Antidepressive Agents ; Antidepressive agents, tricyclic ; Antihistaminic ; Central Nervous System Agents ; Drug / Therapeutic Agent ; Human Data ; Neurotransmitter Agents ; Neurotransmitter Uptake Inhibitors ; Peripheral Nervous System Agents ; Psychotropic Drugs ; Reproductive Effect ; Sensory System Agents
Melting point: 196-197°C 
Index of Refraction: 1.628
Molar Refractivity: 91.52 cm3
Molar Volume: 257.7 cm3
Surface Tension: 47 dyne/cm
Density: 1.076 g/cm3
Flash Point: 174 °C
Enthalpy of Vaporization: 64.88 kJ/mol
Boiling Point: 398.2 °C at 760 mmHg
Vapour Pressure: 1.5E-06 mmHg at 25°C

Amitriptyline Uses

  Amitriptyline (CAS NO.50-48-6) is recommended for the treatment of mental depression, with improvement in mood seen in 2 to 3 weeks after the start of medication. It is now used in the United States and United Kingdom to prevent migraines only in very small doses. It is also used as sleeping aids in small doses of usually 25 mg, and for diabetic retinopathy.

Amitriptyline Production

The synthesis of Amitriptyline (CAS NO.50-48-6) starts from the key intermediate dibenzo-suberone (manufactured from phthalic anhydride) and can proceed by two pathways (Fig. 1). Treatment of dibenzosuberone with cyclopropyl Grignard gives the tertiary alcohol after hydrolysis. Reaction of the alcohol with hydrochloric acid proceeds with rearrangement and opening of the strained cyclopropane to give a chloride. Reaction and displacement of the chlorine atom with dimethylamine forms amitriptyline. Alternatively, dibenzosuberone can be reacted with dimethylaminopropyl Grignard to form an alcohol, which upon dehydration forms amitriptyline.

FIGURE 1 Manufacture of amitriptyline.

Amitriptyline Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 4500ug/kg (4.5mg/kg) BEHAVIORAL: SLEEP British Medical Journal. Vol. 3, Pg. 663, 1967.
dog LDLo subcutaneous 50mg/kg (50mg/kg) PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Pharmacologist. Vol. 11, Pg. 283, 1969.
guinea pig LDLo intravenous 35mg/kg (35mg/kg)   Drugs of the Future. Vol. 8, Pg. 949, 1983.
human TDLo oral 2mg/kg/3D-I (2mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS
British Journal of Clinical Pharmacology. Vol. 49, Pg. 118, 2000.
human TDLo oral 14mg/kg (14mg/kg) CARDIAC: OTHER CHANGES Proceedings of the European Society for the Study of Drug Toxicity. Vol. 6, Pg. 171, 1965.
infant TDLo oral 50mg/kg (50mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

CARDIAC: CHANGE IN RATE

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)
American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976.
man LDLo oral 29mg/kg (29mg/kg)   Human & Experimental Toxicology. Vol. 9, Pg. 257, 1990.
man TDLo oral 1564mg/kg/2Y- (1564mg/kg) PERIPHERAL NERVE AND SENSATION: PARESTHESIS

BEHAVIORAL: ATAXIA

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
Italian Journal of Neurological Sciences. Vol. 9, Pg. 89, 1988.
man TDLo unreported 45mg/kg/21D (45mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

CARDIAC: CHANGE IN RATE
Lancet. Vol. 2, Pg. 1202, 1972.
mouse LD50 intraperitoneal 48400ug/kg (48.4mg/kg)   Farmakologiya i Toksikologiya Vol. 53(4), Pg. 19, 1990.
mouse LD50 intravenous 16mg/kg (16mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) Journal of Medicinal Chemistry. Vol. 17, Pg. 65, 1974.
mouse LD50 oral 99mg/kg (99mg/kg)   Doklady Akademii Nauk SSSR. Proceedings of the Academy of Sciences of the USSR. For English translation, see DBIOAM and DKBSAS. Vol. 335, Pg. 388, 1994.
mouse LD50 subcutaneous 100mg/kg (100mg/kg)   United States Patent Document. Vol. #4605673,
mouse LD50 unreported 80mg/kg (80mg/kg) AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)" Journal of Medicinal Chemistry. Vol. 10, Pg. 418, 1967.
rabbit LD50 intraperitoneal 58700ug/kg (58.7mg/kg) LUNGS, THORAX, OR RESPIRATION: CYANOSIS Journal of Toxicology, Clinical Toxicology. Vol. 19, Pg. 321, 1982.
rabbit LD50 intravenous 8600ug/kg (8.6mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 863, 1965.
rat LD50 intraperitoneal 72mg/kg (72mg/kg)   Polish Journal of Pharmacology and Pharmacy. Vol. 27, Pg. 503, 1975.
rat LD50 oral 320mg/kg (320mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: ATAXIA
Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 863, 1965.
women TDLo intramuscular 240ug/kg/36H- (0.24mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Lancet. Vol. 1, Pg. 390, 1968.
women TDLo oral 13500ug/kg/3D (13.5mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: EXCITEMENT
Lancet. Vol. 1, Pg. 390, 1968.
women TDLo oral 16800ug/kg/2W (16.8mg/kg) PERIPHERAL NERVE AND SENSATION: PARESTHESIS

BEHAVIORAL: HEADACHE
Lancet. Vol. 1, Pg. 426, 1968.
women TDLo oral 18500ug/kg (18.5mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 795, 1993.
women TDLo oral 60mg/kg (60mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

CARDIAC: CHANGE IN RATE

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
Journal of Toxicology, Clinical Toxicology. Vol. 19, Pg. 67, 1982.
women TDLo oral 84mg/kg (84mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE Japanese Journal of Toxicology. Vol. 5, Pg. 69, 1992.

Amitriptyline Safety Profile

Human poison by an unspecified route. Poison experimentally by ingestion, intraperitoneal, subcutaneous, intramuscular, and intravenous routes. Human systemic effects by ingestion and intramuscular routes: changes in sleep, headache, paresthesia, convulsions, excitement, somnolence, muscle contractions, change in heart rate, and other cardiac changes. An experimental teratogen. Other experimental reproductive effects. An antidepressant. When heated to decomposition it emits toxic fumes of NOx.

Amitriptyline Specification

Common side effects of using amitriptyline are mostly due to its anticholinergic activity, including: weight gain, dry mouth, loss of appetite, drowsiness, muscle stiffness, nausea, constipation, nervousness, dizziness, blurred vision, urinary retention and insomnia. Some rare side effects include tinnitus, hypotension, mania, psychosis, heart block, arrhythmias, lip and mouth ulcers, extrapyramidal symptoms, depression, and hepatic toxicity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50-48-6